Want to see APYX full AI Analyst Report?
APYX Stock Chart & Stats
$3.92
-$0.03(-0.77%)
At close: 4:00 PM EDT
$3.92
-$0.03(-0.77%)
Day’s Range― - ―
52-Week Range$1.70 - $5.08
Previous Close$3.83
Volume71.39K
Average Volume (3M)120.72K
Market Cap
$127.21M
Enterprise Value$209.33
Total Cash (Recent Filing)$27.62M
Total Debt (Recent Filing)$39.63M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding42,124,023
10 Day Avg. Volume65,017
30 Day Avg. Volume120,723
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside65.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$59.55M
Bulls Say, Bears Say
Bulls Say
Razor-and-blades Recurring Consumables ModelApyx’s business model ties capital system placements to repeat consumable demand, creating durable, higher-frequency revenue as procedure volumes rise. An expanding installed base magnifies lifetime value per system, supporting margin stability and predictable recurring revenue as adoption scales.
Surgical Aesthetics Commercial MomentumSustained double-digit growth in Surgical Aesthetics reflects product-market fit for AYON and growing procedure throughput. This segment drives both capital placements and higher-margin consumables, reinforcing revenue durability, improving gross profit mix, and providing a foundation for scaling sales and marketing investments over multiple years.
Regulatory/product Expansion (AYON Power Lipo)FDA 510(k) expansion materially broadens AYON’s addressable uses and enables an integrated platform offering. Early shipments and management expectations of high attach rates for Power Lipo should increase system utility and consumable attach, strengthening competitive positioning and supporting durable revenue and margin improvement as adoption widens.
Bears Say
Elevated Leverage And Thin Equity CushionMaterial debt relative to a compressed equity base reduces financial flexibility and raises refinancing or covenant risk if cash generation stalls. Elevated leverage constrains the company’s ability to fund manufacturing scale, absorb execution hiccups, or pursue opportunistic M&A without dilutive capital raises or higher-cost financing.
Persistent Negative Cash GenerationOngoing negative operating and free cash flow implies the business still consumes external capital to fund growth and operations. Until cash-flow breakeven, management must rely on financing or drawdowns, which can dilute shareholders, limit reinvestment in commercialization, and increase vulnerability to cost or demand shocks.
Profitability And Margin Recovery IncompleteWhile losses have narrowed, margins remain depressed versus prior peaks and the company has not reached sustainable profitability. Gross margin erosion and negative net margins require sustained volume, pricing/mix shifts, and manufacturing cost reductions to maintain improvements and justify reinvestment without recurring losses.
Apyx Medical News
APYX FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was $1.70 and its highest was $5.08 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is $127.21M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 84 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.012.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.1.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 42,124,023 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -2.644%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in APYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (65.82% Upside)
$6.50 (65.82% Upside)
Blogger Sentiment
Bearish
APYX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 168.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
APYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.View all APYX earnings summariesAPYX Stock 12 Month Forecast
Average Price Target
$6.50
▲(65.82% Upside)
Technical Analysis
Ownership Overview
6.77% Insiders
8.83% Mutual Funds
12.40% Other Institutional Investors
68.01% Public Companies and
Individual Investors